Loading...

Actinium Pharmaceuticals

DB:7AY
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7AY
DB
$37M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Actinium Pharmaceuticals has significant price volatility in the past 3 months.
7AY Share Price and Events
7 Day Returns
-29.1%
DB:7AY
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
21.8%
DB:7AY
-10.6%
DE Biotechs
-6.2%
DE Market
7AY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Actinium Pharmaceuticals (7AY) -29.1% -40.1% -13.7% 21.8% -83.7% -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 7AY outperformed the Biotechs industry which returned -10.6% over the past year.
  • 7AY outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
7AY
Industry
5yr Volatility vs Market
Related Companies

7AY Value

 Is Actinium Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Actinium Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Actinium Pharmaceuticals.

DB:7AY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:7AY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0.71%))
1.305
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.305 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:7AY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Actinium Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:7AY DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -10.60 Analyst x1 -9.81
2020 14.00 Analyst x1 12.00
2021 42.10 Analyst x1 33.41
2022 94.70 Analyst x1 69.59
2023 188.10 Analyst x1 127.97
2024 222.49 Est @ 18.29% 140.15
2025 251.12 Est @ 12.87% 146.46
2026 273.92 Est @ 9.08% 147.90
2027 291.51 Est @ 6.42% 145.73
2028 304.81 Est @ 4.56% 141.08
Present value of next 10 years cash flows $954.48
DB:7AY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $304.81 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$3,926.91
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,926.91 ÷ (1 + 8.01%)10
$1,817.61
DB:7AY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $954.48 + $1,817.61
$2,772.09
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,772.09 / 119.14
$23.27
DB:7AY Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:7AY represents 0.93548x of AMEX:ATNM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.93548x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 23.27 x 0.93548
€21.77
Value per share (EUR) From above. €21.77
Current discount Discount to share price of €0.29
= -1 x (€0.29 - €21.77) / €21.77
98.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Actinium Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €0.29 vs Future cash flow value of €21.77
Current Discount Checks
For Actinium Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Actinium Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Actinium Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Actinium Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Actinium Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7AY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.22
AMEX:ATNM Share Price ** AMEX (2019-04-18) in USD $0.31
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Actinium Pharmaceuticals.

DB:7AY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:ATNM Share Price ÷ EPS (both in USD)

= 0.31 ÷ -0.22

-1.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Actinium Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Actinium Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Actinium Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:7AY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
62.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Actinium Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Actinium Pharmaceuticals's assets?
Raw Data
DB:7AY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.08
AMEX:ATNM Share Price * AMEX (2019-04-18) in USD $0.31
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:7AY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:ATNM Share Price ÷ Book Value per Share (both in USD)

= 0.31 ÷ 0.08

4.07x

* Primary Listing of Actinium Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Actinium Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Actinium Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Actinium Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7AY Future Performance

 How is Actinium Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Actinium Pharmaceuticals expected to grow at an attractive rate?
  • Actinium Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Actinium Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Actinium Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:7AY Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7AY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 62.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7AY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7AY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 348 188 201 2
2022-12-31 243 121 148 3
2021-12-31 106 43 42 3
2020-12-31 38 14 -6 3
2019-12-31 0 -10 -27 3
DB:7AY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -21 -24
2018-09-30 -19 -22
2018-06-30 -19 -23
2018-03-31 -22 -25
2017-12-31 -22 -27
2017-09-30 -23 -28
2017-06-30 -22 -28
2017-03-31 -21 -28
2016-12-31 -21 -24
2016-09-30 -21 -24
2016-06-30 -18 -22
2016-03-31 -17 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Actinium Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Actinium Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7AY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Actinium Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7AY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.32 1.33 1.30 2.00
2022-12-31 0.91 1.21 0.70 3.00
2021-12-31 0.26 0.33 0.15 3.00
2020-12-31 -0.03 0.10 -0.17 3.00
2019-12-31 -0.20 -0.18 -0.23 3.00
DB:7AY Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.22
2018-09-30 -0.23
2018-06-30 -0.26
2018-03-31 -0.33
2017-12-31 -0.40
2017-09-30 -0.46
2017-06-30 -0.52
2017-03-31 -0.54
2016-12-31 -0.50
2016-09-30 -0.54
2016-06-30 -0.50
2016-03-31 -0.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Actinium Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Actinium Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Actinium Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7AY Past Performance

  How has Actinium Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Actinium Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Actinium Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Actinium Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Actinium Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Actinium Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Actinium Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7AY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -23.65 6.73 17.09
2018-09-30 -22.50 6.96 15.66
2018-06-30 -22.67 6.66 16.47
2018-03-31 -24.85 7.82 17.59
2017-12-31 -26.60 9.19 17.72
2017-09-30 -28.13 10.23 18.24
2017-06-30 -28.41 9.97 18.89
2017-03-31 -27.98 9.98 18.59
2016-12-31 -24.32 9.02 17.83
2016-09-30 -24.17 8.68 16.20
2016-06-30 -21.51 9.08 13.34
2016-03-31 -22.35 9.88 13.03
2015-12-31 -21.03 11.27 13.50
2015-09-30 -19.91 11.60 15.12
2015-06-30 -22.04 12.70 16.43
2015-03-31 -11.06 11.43 14.73
2014-12-31 -24.69 10.18 12.27
2014-09-30 -25.14 8.47 8.60
2014-06-30 -20.49 6.41 5.23
2014-03-31 -26.78 5.09 3.61
2013-12-31 -10.77 3.48 3.11
2013-09-30 -7.77 5.72 3.09
2013-06-30 -9.36 5.61 3.99
2013-03-31 -8.14 4.88 4.08
2012-12-31 -8.36 4.51 3.44
2012-09-30 -8.32 4.10 2.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Actinium Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Actinium Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Actinium Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Actinium Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Actinium Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7AY Health

 How is Actinium Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Actinium Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Actinium Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Actinium Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Actinium Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 54.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Actinium Pharmaceuticals Company Filings, last reported 3 months ago.

DB:7AY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 8.81 0.26 13.67
2018-09-30 11.58 0.00 14.81
2018-06-30 17.32 0.00 21.47
2018-03-31 21.75 0.00 26.76
2017-12-31 13.67 0.00 17.40
2017-09-30 18.19 0.00 20.54
2017-06-30 8.87 0.00 11.46
2017-03-31 12.88 0.00 17.09
2016-12-31 18.01 0.00 20.52
2016-09-30 14.23 0.00 15.53
2016-06-30 19.08 0.09 20.46
2016-03-31 20.06 0.18 22.21
2015-12-31 21.97 0.27 25.64
2015-09-30 22.89 0.00 24.76
2015-06-30 23.28 0.09 25.95
2015-03-31 16.44 0.19 19.28
2014-12-31 -1.92 0.28 6.71
2014-09-30 2.37 0.00 11.75
2014-06-30 4.33 0.05 14.67
2014-03-31 -13.47 0.09 5.88
2013-12-31 -1.56 0.16 5.53
2013-09-30 0.60 0.00 3.99
2013-06-30 1.91 0.04 5.65
2013-03-31 0.55 0.07 3.24
2012-12-31 1.15 0.14 5.62
2012-09-30 -4.00 0.80 2.57
  • Actinium Pharmaceuticals's level of debt (3%) compared to net worth is satisfactory (less than 40%).
  • Actinium Pharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Actinium Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Actinium Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.1% each year.
X
Financial health checks
We assess Actinium Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Actinium Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7AY Dividends

 What is Actinium Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Actinium Pharmaceuticals dividends.
If you bought €2,000 of Actinium Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Actinium Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Actinium Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7AY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7AY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Actinium Pharmaceuticals has not reported any payouts.
  • Unable to verify if Actinium Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Actinium Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Actinium Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Actinium Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Actinium Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Actinium Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7AY Management

 What is the CEO of Actinium Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sandesh Seth
COMPENSATION $1,374,253
AGE 54
TENURE AS CEO 1.8 years
CEO Bio

Mr. Sandesh C. Seth, M.S., MBA has been Chief Executive Officer of Actinium Pharmaceuticals, Inc. since June 5, 2017. Mr. Seth serves as the Head of Healthcare Investment Banking at Laidlaw & Company (UK) Ltd. Mr. Seth has been the Executive Chairman and Director of Actinium Pharmaceuticals, Inc. since October 2013 and March 2012 respectively. Prior to this, he served as the Managing Partner at AmerAsia Capital Partners, LLC. He also founded the firm. Prior to that, He served as an Investment Banker at SG Cowen & Co. LLC. Prior to that, he served as an Equity Analyst at Bear Stearns Companies Inc., Research Division. Prior to that, Mr. Seth was at Commonwealth Associates, Inc. where he covered the life sciences sector. He served as a Research Analyst at Commonwealth Associates L.P., Research Division. As part of his financial services experience, He was also involved with various strategic initiatives such as mergers and acquisitions, leveraged and management buy-outs and licensing and joint ventures, including the $100 billion merger of Pfizer and Warner-Lambert and the $20 billion merger of Pharmacia & Upjohn with Monsanto. In addition, he has over seven years of pharmaceutical industry experience including R&D project management, marketing and strategic planning at SmithKline Beecham Inc., Warner-Lambert & Co., and Pfizer Inc respectively. He served as the Chairman of Relmada Therapeutics, Inc. from June 2015 to June 6, 2017. He served as Director of Relmada Therapeutics, Inc. from October 2012 to June 6, 2017 and served as its Lead Director since January 2014. He served as a Director of Cactus Ventures, Inc., since December 28, 2012. He has over 20 years of experience in merchant and investment banking, equity research at Cowen & Co., Bear Stearns and Commonwealth Associates and in the pharma industry at Pfizer, Warner-Lambert and SmithKline. Mr. Seth has published and presented several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. He was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signified proficiency with U.S. FDA regulations. Mr. Seth is also registered with the NASD as a General Securities Representative (Series 7, 79 and 63). He has an M.B.A. in Finance from New York University, an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University.

CEO Compensation
  • Sandesh's compensation has increased whilst company is loss making.
  • Sandesh's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Actinium Pharmaceuticals management team in years:

1.3
Average Tenure
54
Average Age
  • The average tenure for the Actinium Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Sandesh Seth

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
54
TENURE
1.8 yrs

Steve O'Loughlin

TITLE
Principal Financial & Accounting Officer
COMPENSATION
$506K
AGE
32
TENURE
1.9 yrs

Dale Ludwig

TITLE
Chief Scientific Officer
COMPENSATION
$425K
AGE
56
TENURE
1.3 yrs

Mark Berger

TITLE
Chief Medical Officer
COMPENSATION
$612K
AGE
63
TENURE
2.3 yrs

Anil Kapur

TITLE
Chief Commercial Officer
COMPENSATION
$506K
AGE
49
TENURE
1.2 yrs

David Gould

TITLE
Senior Vice President of Corporate Development & Corporate Affairs

Bernie Cunningham

TITLE
Executive Director of Clinical Supply Chain & Logistics and CMC Project Management
TENURE
2.5 yrs

Qing Liang

TITLE
VP & Head of Radiation Sciences
TENURE
0.3 yrs

Cynthia Pussinen

TITLE
Executive Vice President of Technical Operations & Supply Chain
TENURE
0.3 yrs

Robert Daly

TITLE
VP & Head of Clinical Operations
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Actinium Pharmaceuticals board of directors in years:

3.8
Average Tenure
62
Average Age
  • The tenure for the Actinium Pharmaceuticals board of directors is about average.
Board of Directors

Sandesh Seth

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
54
TENURE
5.5 yrs

Joseph Jurcic

TITLE
Chairman of Clinical Advisory Board

John Pagel

TITLE
Chairman of Scientific Advisory Board & Member of Clinical Advisory Board

C. Nicholson

TITLE
Lead Independent Director
COMPENSATION
$105K
AGE
63
TENURE
1.6 yrs

Rich Steinhart

TITLE
Independent Director
COMPENSATION
$107K
AGE
61
TENURE
5.4 yrs

Ajit Shetty

TITLE
Director
COMPENSATION
$100K
AGE
71
TENURE
2.1 yrs

Elihu Estey

TITLE
Member of Clinical Advisory Board

Alexander Perl

TITLE
Member of Clinical Advisory Board

Richard Wahl

TITLE
Member of Clinical Advisory Board

David Scheinberg

TITLE
Member of Clinical Advisory Board
AGE
62
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
10. Dec 18 Buy Sandesh Seth Individual 10. Dec 18 10. Dec 18 10,000 €0.38 €3,846
10. Dec 18 Buy Steven O'Loughlin Individual 10. Dec 18 10. Dec 18 10,000 €0.38 €3,827
20. Nov 18 Buy Dale Ludwig Individual 19. Nov 18 19. Nov 18 10,000 €0.39 €3,928
17. Jul 18 Buy Sandesh Seth Individual 17. Jul 18 17. Jul 18 10,000 €0.68 €6,758
15. Jun 18 Buy Steven O'Loughlin Individual 15. Jun 18 15. Jun 18 12,000 €0.43 €5,162
X
Management checks
We assess Actinium Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Actinium Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7AY News

Simply Wall St News

7AY Company Info

Description

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Details
Name: Actinium Pharmaceuticals, Inc.
7AY
Exchange: DB
Founded: 2000
$32,840,086
119,136,036
Website: http://www.actiniumpharma.com
Address: Actinium Pharmaceuticals, Inc.
275 Madison Avenue,
7th Floor,
New York,
New York, 10016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX ATNM New Common Stock NYSE MKT LLC US USD 30. Dec 2012
DB 7AY New Common Stock Deutsche Boerse AG DE EUR 30. Dec 2012
Number of employees
Current staff
Staff numbers
30
Actinium Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:58
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/27
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.